In recent years, two KRAS G12C inhibitors, sotorasib and adagrasib, have been approved by the United States Food and Drug Administration (US FDA) for the treatment of patients with locally advanced or metastatic non-small-cell lung cancer (NSCLC),8,9 but not in mCRC as monotherapy as to date. Here, KRAS is linked to non-small cell lung carcinoma.